Mr Alistair Taylor

Non-Executive Chairman

Mr Taylor is currently Executive Chairman of UK listed Lombard Medical Technologies plc and has 45 years experience in the healthcare industry, ten years in pharmaceuticals and 35 years in medical devices. He was Chief Executive Officer of Biocompatibles International plc from 1994 to 1998 and during this period the company progressed from a technology-based start up company, through flotation to a FTSE 250 company. Prior to this, Mr Taylor was Chief Executive Officer of Schneider Inc, a Swiss interventional cardiology/radiology device company and during this time the company’s turnover grew to $100 million. Schneider was subsequently sold by Pfizer Inc., its parent, for over $2 billion. Mr Taylor’s early career included the Chief Accountant role at Beecham Pharmaceuticals. He is also Chairman of Starbridge Systems Limited and a Non-Executive Director of Vascular Concepts Limited.

Committees:

Dr Daryl Rees

Chief Executive Officer

Dr Daryl Rees has a MSc in Pharmacology and a PhD in Clinical Pharmacology. Dr Rees joined Phytopharm in June 1999 from University College London where he was a senior lecturer in Clinical Pharmacology. Prior to this Dr Rees gained 10 years' experience in the discovery and clinical development of medicines as a senior scientist at Wellcome and was part of a multidisciplinary team involved in the discovery of the L-arginine- NO pathway. He is an honorary senior lecturer in the Department of Medicine at University College London, a former editor of the British Journal of Pharmacology and is chairman of an accredited Research Ethics Committee.

Mr Piers Morgan

Chief Financial Officer

Mr Morgan has an MA in Law and Management Studies from Cambridge University and is a Chartered Accountant. He worked at Close Brothers Corporate Finance on a wide variety of Equity Capital Market and Mergers & Acquisitions transactions and was a founding director of the Life Sciences Mergers & Acquisitions team at Ernst & Young. In 2000, he joined Arrow Therapeutics Limited (acquired by Astra Zeneca for $150m) as Finance Director, raising significant finance through private equity, debt and grants. In 2005, he moved to Paris to become Chief Financial Officer of BioAlliance SA, where he led the successful flotation of the company on Euronext Paris.

Mr A D (Sandy) Morrison

Non-Executive Director

Mr Morrison has a BSc (Hons) in applied chemistry (Strathclyde) and has over 20 years experience in general and international management, global supply chain and R&D. He was Chief Executive Officer of Lipton Ltd, the global tea sourcing organization for Unilever with operations in six countries for five years from 2000 to 2006. During Mr Morrison's period as CEO, substantial operational & financial improvements were made to the Unilever global tea supply chain and he also played a significant part in addressing issues in the international tea trade. In the immediate years prior to 2000, Mr Morrison had senior international food & beverage roles for Unilever outside the UK, in the supply chain and in R&D, both at the Rotterdam head office and in the Unilever food and beverage subsidiary in Australia.

Committees:

Dr Peter Blower

Non-Executive Director

Dr Blower has over 30 years experience in medicinal research and development with a strong background in the field of neuroscience. Dr Blower joined Beecham Research Laboratories in 1969 and rose to the position of Director of New Neuroscience products in 1996 before leaving in 2000 to form his own consultancy company. He has been elected to Fellowship of the Royal Society of Medicine and the Institute of Biology and has authored over 50 scientific publications. He has a M.I.Biol from the Institute of Biology (1972), a PhD in Pharmacology from the University of Aston (1977) and a DSc from the University of East London (1997).

Committees: